Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
8357 | 1262 | 32.2 | 70% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
176 | 3 | DIABETES CARE//ENDOCRINOLOGY & METABOLISM//TYPE 2 DIABETES | 58057 |
1896 | 2 | METFORMIN//ACARBOSE//REPAGLINIDE | 5944 |
8357 | 1 | ACARBOSE//ALPHA GLUCOSIDASE INHIBITOR//MIGLITOL | 1262 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | ACARBOSE | authKW | 1828187 | 15% | 41% | 184 |
2 | ALPHA GLUCOSIDASE INHIBITOR | authKW | 1301905 | 12% | 34% | 157 |
3 | MIGLITOL | authKW | 903219 | 4% | 67% | 56 |
4 | ALPHA GLUCOSIDASE | authKW | 687923 | 13% | 17% | 170 |
5 | POSTPRANDIAL HYPERGLYCEMIA | authKW | 289330 | 4% | 24% | 50 |
6 | VOGLIBOSE | authKW | 221176 | 2% | 38% | 24 |
7 | ALPHA GLUCOSIDASE INHIBITION | authKW | 197441 | 3% | 20% | 40 |
8 | HPLC HRMS SPE NMR | authKW | 178155 | 1% | 82% | 9 |
9 | AMINOOLIGOSACCHARIDE | authKW | 145166 | 0% | 100% | 6 |
10 | TOUCHI EXTRACT | authKW | 145166 | 0% | 100% | 6 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Endocrinology & Metabolism | 4235 | 23% | 0% | 290 |
2 | Food Science & Technology | 2276 | 16% | 0% | 205 |
3 | Pharmacology & Pharmacy | 1520 | 22% | 0% | 278 |
4 | Nutrition & Dietetics | 1466 | 10% | 0% | 120 |
5 | Chemistry, Medicinal | 1216 | 10% | 0% | 124 |
6 | Chemistry, Applied | 1120 | 10% | 0% | 120 |
7 | Integrative & Complementary Medicine | 1057 | 4% | 0% | 46 |
8 | Medicine, General & Internal | 266 | 8% | 0% | 105 |
9 | Medicine, Research & Experimental | 155 | 5% | 0% | 67 |
10 | Agriculture, Multidisciplinary | 123 | 2% | 0% | 31 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | HIGASHISONOGI TEA BRANCH | 72583 | 0% | 100% | 3 |
2 | FOOD BIOCHEMKITA KU | 61927 | 1% | 32% | 8 |
3 | BIOL ENGN FOOD IND | 48389 | 0% | 100% | 2 |
4 | TIANJIN STATE CELLULAR MOL IMMUNOL | 48389 | 0% | 100% | 2 |
5 | HUA XI MED | 46521 | 0% | 38% | 5 |
6 | BEST CELLULAR NUTR | 32258 | 0% | 67% | 2 |
7 | GEN FOODS | 32258 | 0% | 67% | 2 |
8 | REQUIMTELAQV FARMACOGNOSIA | 32258 | 0% | 67% | 2 |
9 | PHYTOMED PHYTOPHARMACOL GRP | 32250 | 0% | 22% | 6 |
10 | MED FOOD DEV | 26290 | 0% | 22% | 5 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | DIABETES RESEARCH AND CLINICAL PRACTICE | 6550 | 3% | 1% | 38 |
2 | JOURNAL OF FOOD BIOCHEMISTRY | 4372 | 1% | 1% | 17 |
3 | DIABETES NUTRITION & METABOLISM | 3064 | 1% | 1% | 9 |
4 | DIABETES CARE | 3011 | 3% | 0% | 38 |
5 | DIABETES OBESITY & METABOLISM | 2786 | 1% | 1% | 16 |
6 | METABOLISM-CLINICAL AND EXPERIMENTAL | 2753 | 3% | 0% | 32 |
7 | FOOD SCIENCE AND BIOTECHNOLOGY | 2682 | 2% | 1% | 19 |
8 | NUTRITION RESEARCH AND PRACTICE | 1930 | 1% | 1% | 7 |
9 | CLINICAL DRUG INVESTIGATION | 1851 | 1% | 1% | 13 |
10 | DIABETIC MEDICINE | 1669 | 2% | 0% | 20 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | ACARBOSE | 1828187 | 15% | 41% | 184 | Search ACARBOSE | Search ACARBOSE |
2 | ALPHA GLUCOSIDASE INHIBITOR | 1301905 | 12% | 34% | 157 | Search ALPHA+GLUCOSIDASE+INHIBITOR | Search ALPHA+GLUCOSIDASE+INHIBITOR |
3 | MIGLITOL | 903219 | 4% | 67% | 56 | Search MIGLITOL | Search MIGLITOL |
4 | ALPHA GLUCOSIDASE | 687923 | 13% | 17% | 170 | Search ALPHA+GLUCOSIDASE | Search ALPHA+GLUCOSIDASE |
5 | POSTPRANDIAL HYPERGLYCEMIA | 289330 | 4% | 24% | 50 | Search POSTPRANDIAL+HYPERGLYCEMIA | Search POSTPRANDIAL+HYPERGLYCEMIA |
6 | VOGLIBOSE | 221176 | 2% | 38% | 24 | Search VOGLIBOSE | Search VOGLIBOSE |
7 | ALPHA GLUCOSIDASE INHIBITION | 197441 | 3% | 20% | 40 | Search ALPHA+GLUCOSIDASE+INHIBITION | Search ALPHA+GLUCOSIDASE+INHIBITION |
8 | HPLC HRMS SPE NMR | 178155 | 1% | 82% | 9 | Search HPLC+HRMS+SPE+NMR | Search HPLC+HRMS+SPE+NMR |
9 | AMINOOLIGOSACCHARIDE | 145166 | 0% | 100% | 6 | Search AMINOOLIGOSACCHARIDE | Search AMINOOLIGOSACCHARIDE |
10 | TOUCHI EXTRACT | 145166 | 0% | 100% | 6 | Search TOUCHI+EXTRACT | Search TOUCHI+EXTRACT |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | JOSHI, SR , STANDL, E , TONG, NW , SHAH, P , KALRA, S , RATHOD, R , (2015) THERAPEUTIC POTENTIAL OF ALPHA-GLUCOSIDASE INHIBITORS IN TYPE 2 DIABETES MELLITUS: AN EVIDENCE-BASED REVIEW.EXPERT OPINION ON PHARMACOTHERAPY. VOL. 16. ISSUE 13. P. 1959 -1981 | 78 | 55% | 9 |
2 | VAN DE LAAR, FA , LUCASSEN, PLBJ , AKKERMANS, RP , VAN DE LISDONK, EH , RUTTEN, GEHM , VAN WEEL, C , (2005) ALPHA-GLUCOSIDASE INHIBITORS FOR TYPE 2 DIABETES MELLITUS (REVIEW) - ART. NO. CD003639.PUB2.COCHRANE DATABASE OF SYSTEMATIC REVIEWS. VOL. . ISSUE 2. P. - | 57 | 85% | 63 |
3 | VAN DE LAAR, FA , LUCASSEN, PL , AKKERMANS, RP , VAN DE LISDONK, FH , RUTTEN, GE , VAN WEEL, C , (2005) ALPHA-GLUCOSIDASE INHIBITORS FOR PATIENTS WITH TYPE 2 DIABETES - RESULTS FROM A COCHRANE SYSTEMATIC REVIEW AND META-ANALYSIS.DIABETES CARE. VOL. 28. ISSUE 1. P. 154-163 | 43 | 91% | 189 |
4 | CAI, XL , HAN, XY , LUO, YY , JI, LN , (2013) COMPARISONS OF THE EFFICACY OF ALPHA GLUCOSIDASE INHIBITORS ON TYPE 2 DIABETES PATIENTS BETWEEN ASIAN AND CAUCASIAN.PLOS ONE. VOL. 8. ISSUE 11. P. - | 50 | 78% | 2 |
5 | LAUBE, H , (2002) ACARBOSE - AN UPDATE OF ITS THERAPEUTIC USE IN DIABETES TREATMENT.CLINICAL DRUG INVESTIGATION. VOL. 22. ISSUE 3. P. 141 -156 | 57 | 85% | 46 |
6 | LEBOVITZ, HE , (1998) ALPHA-GLUCOSIDASE INHIBITORS AS AGENTS IN THE TREATMENT OF DIABETES.DIABETES REVIEWS. VOL. 6. ISSUE 2. P. 132-145 | 50 | 85% | 120 |
7 | SCHEEN, AJ , (1998) CLINICAL EFFICACY OF ACARBOSE IN DIABETES MELLITUS: A CRITICAL REVIEW OF CONTROLLED TRIALS.DIABETES & METABOLISM. VOL. 24. ISSUE 4. P. 311 -320 | 45 | 94% | 42 |
8 | SCHEEN, AJ , (2003) IS THERE A ROLE FOR ALPHA-GLUCOSIDASE INHIBITORS IN THE PREVENTION OF TYPE 2 DIABETES MELLITUS?.DRUGS. VOL. 63. ISSUE 10. P. 933 -951 | 57 | 59% | 75 |
9 | KUMAR, RV , SINHA, VR , (2012) NEWER INSIGHTS INTO THE DRUG DELIVERY APPROACHES OF ALPHA-GLUCOSIDASE INHIBITORS.EXPERT OPINION ON DRUG DELIVERY. VOL. 9. ISSUE 4. P. 403 -416 | 37 | 73% | 5 |
10 | BREUER, HWM , (2003) REVIEW OF ACARBOSE THERAPEUTIC STRATEGIES IN THE LONG-TERM TREATMENT AND IN THE PREVENTION OF TYPE 2 DIABETES.INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS. VOL. 41. ISSUE 10. P. 421-440 | 57 | 55% | 49 |
Classes with closest relation at Level 1 |